Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

Fig. 4

ACR20, ACR50, and ACR70 response rates up to week 48 (TP2 per-protocol set). TP2 PPS comprised of all patients completing the study until week 48 without major protocol deviations. ACR, American College of Rheumatology; PPS, per-protocol set; TP, treatment period

Back to article page